Aberrant FLT3 receptor seemed to be an attractive therapeutic target in AML, so several small molecules FLT3 tyrosine kinase inhibitors (TKI) have been developed and examined in vitro and in vivo. Here, FLT3 is linked to acute myeloid leukemia.